SCHEMBL25544329

SCHEMBL25544329

Cc1ccc2c(-c3ccc(F)c(C)c3)c(C(C)C)c(Cl)nc2c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 3/20 0.36
DHODH Q02127 1/20 0.36
TRPV1 Q8NER1 1/20 0.34
TRPV3 Q8NET8 1/20 0.34
ACHE P22303 4/20 0.33
KMT2A Q03164 2/20 0.33
NPSR1 Q6W5P4 1/20 0.33
BCHE P06276 3/20 0.32
GRIN1 Q05586 3/20 0.32
GRIN2A Q12879 3/20 0.32
ALDH1A1 P00352 2/20 0.32
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
MAPT P10636 1/20 0.32
MPI P34949 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
POLB P06746 1/20 0.32
GRIN2B Q13224 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
SRC P12931 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23887792 0.86 KDM4E (0.37) TRPV1ACHEKMT2ANPSR1ALDH1A1
SCHEMBL30367801 0.86 KDM4E (0.37) TRPV1ACHEKMT2ANPSR1ALDH1A1
SCHEMBL25544324 0.86 GRM2 (0.43) GRM2DHODHKMT2ANPSR1ALDH1A1
SCHEMBL30121025 0.79 MEN1 (0.41) DHODHACHEKMT2AMEN1MAPT
SCHEMBL23887795 0.79 MEN1 (0.41) DHODHACHEKMT2AMEN1MAPT
SCHEMBL25544512 0.77 GCGR (0.34) GRM2DHODHTRPV1TRPV3GRIN2B
SCHEMBL25544325 0.76 GRIN2B (0.40) GRIN1GRIN2B
SCHEMBL25544371 0.74 GRIN2B (0.34) GRM2DHODHACHEBCHEGRIN1
SCHEMBL25544237 0.74 PTGS2 (0.36) GRM2DHODHTRPV3KMT2AALDH1A1
SCHEMBL25544820 0.74 TRPV3 (0.37) GRM2TRPV3SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159504-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159504-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) SERPINA2, SERPINB1, SERPINE1 GRM2 4755/4885DHODH 379/4885TRPV1 4820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.